Marc Goodman
Stock Analyst at Leerink Partners
(2.89)
# 1,576
Out of 4,843 analysts
96
Total ratings
54.17%
Success rate
26.21%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $5.15 | +94.17% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $105.16 | +42.64% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.75 | +33.33% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $14.81 | +305.13% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $29.20 | +9.59% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $64.87 | -61.46% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $13.24 | +277.64% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $9.19 | +117.63% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $123.02 | -6.52% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $129.79 | +138.85% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $9.11 | +31.72% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $28.85 | +59.45% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $21.57 | -2.64% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $108.07 | +94.32% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $6.46 | +519.20% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.71 | +484.80% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $30.61 | -11.79% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $2.15 | +597.67% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $471.46 | -42.73% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $186.11 | -48.42% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.28 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $76.84 | -12.81% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $26.77 | +266.08% | 7 | Oct 5, 2017 |
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $5.15
Upside: +94.17%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $105.16
Upside: +42.64%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.75
Upside: +33.33%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $14.81
Upside: +305.13%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $29.20
Upside: +9.59%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $64.87
Upside: -61.46%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $13.24
Upside: +277.64%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $9.19
Upside: +117.63%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $123.02
Upside: -6.52%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $129.79
Upside: +138.85%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $9.11
Upside: +31.72%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $28.85
Upside: +59.45%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $21.57
Upside: -2.64%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $108.07
Upside: +94.32%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $6.46
Upside: +519.20%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.71
Upside: +484.80%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $30.61
Upside: -11.79%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $2.15
Upside: +597.67%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $471.46
Upside: -42.73%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $186.11
Upside: -48.42%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $48.28
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $76.84
Upside: -12.81%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $26.77
Upside: +266.08%